國藥(01099.HK):未來進一步推動業務內生式增長
國藥控股(01099.HK)表示,目前對未來毛利率數字難以預測,又指要視乎內地政府推行政策,從而去配合行業未來的發展趨勢。集團表示,未來會進一步加速數字化、智能化等轉型模式,朝向「專業的全國一體化服務」方向,預料未來3至5年內,整個轉型步伐將會有一個集中增長。
集團表示,當政府密集實施醫改政策,包括「帶量採購」、「國家醫保談判」、「按病種付費」等,將會令藥械價格下降、放緩傳統業務增速、以及毛利率承壓,預料這將會成爲行業要面對的另一挑戰,同時這將會推動行業服務需求轉變和分配機制重構。
集團表示,未來進一步推動業務內生式增長,擴大終端網絡覆蓋,持續提升醫療機構直銷業務與零售直銷業務份額,鞏固市場領先優勢。(ca/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.